1. Scrip
  2. >>Business
  3. >>Strategy

Sesen Bio Looks To Partner Vicineum To Save Money As It Mulls Future Strategy

 
• By Alaric DeArment

The company, after revealing in May that it was evaluating various partnership or buyout strategies, also said it would sell its IL-6 programs to Roche as it pauses Vicineum’s US development.

Sesen Bio said it would look to partner Vicineum • Source: Shutterstock

Sesen Bio, Inc. is selling off a portfolio of anti-interleukin-6 (IL-6) antibodies to collaborator Roche Holding AG and looking to find a partner for its lead oncology asset, Vicineum, which was the subject of a complete response letter in 2021, with an eye toward saving money as the company maps out a new strategy following a meeting with the US Food and Drug Administration.

Sesen said on 18 July that it would pause further development of Vicineum (oportuzumab monatox) in the US after what it called a “thorough reassessment” that included the timeline and cost for an additional Phase III trial of the drug in non-muscle invasive bladder cancer (NMIBC) following recent discussions with the FDA

More from Strategy

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.